Maxim Group Initiates Coverage On Acrivon Therapeutics with Buy Rating, Announces Price Target of $24

Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.